Skip to main content
SpringerLink
Log in

Targeted Agents and Immunotherapy

  • Chapter
  • First Online:
Book cover Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy

  • 1338 Accesses

Abstract

This review discussed the role of targeted and immunotherapy in the management of brain metastases. Until recently there was limited role of medical therapies in the brain metastases. This chapter will focus on recently discovered driver mutations in lung cancer, breast cancer, and melanoma, therapies that target such mutations and the outcomes with such approach. We discuss the unique genetic alterations in brain metastases as compared to the primary tumor. We highlight the importance of individualizing systemic treatments. In addition, there is a section on the immunotherapy agents and the results of initial trials in brain metastases with these agents.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the metropolitan detroit cancer surveillance system. J Clin Oncol. 2004;22(14):2865–72.

    Article  PubMed  Google Scholar 

  2. Tabouret E, Chinot O, Metellus P, Tallet A, Viens P, Gonçalves A. Recent trends in epidemiology of brain metastases: an overview. Anticancer Res. 2012 Nov;32(11):4655–62.

    PubMed  Google Scholar 

  3. Sperduto PW, Chao ST, Sneed PK, Luo X, Suh J, Roberge D, et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol. 2010;77(3):655–61.

    Article  Google Scholar 

  4. Chen G, Chakravarti N, Aardalen K, Lazar AJ, Tetzlaff MT, Wubbenhorst B, et al. Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target. Clin Cancer Res. NIH Public Access. 2014;20(21):5537–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Brastianos PK, Carter SL, Santagata S, Cahill DP, Taylor-Weiner A, Jones RT, et al. Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets. Cancer Discov. American Association for Cancer Research. 2015;5(11):1164–77.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Eichler AF, Chung E, Kodack DP, Loeffler JS, Fukumura D, Jain RK. The biology of brain metastases—translation to new therapies. Nat Rev Clin Oncol. 2011;8(6):344–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Fortin D. The blood-brain barrier: its influence in the treatment of brain tumors metastases. Curr Cancer Drug Targets. 2012;12(3):247–59.

    Article  CAS  PubMed  Google Scholar 

  8. Muldoon LL, Soussain C, Jahnke K, Johanson C, Siegal T, Smith QR, et al. Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol. 2007;25(16):2295–305.

    Article  CAS  PubMed  Google Scholar 

  9. Chen J, Xiao L, Rao JN, Zou T, Liu L, Bellavance E, et al. JunD represses transcription and translation of the tight junction protein zona occludens-1 modulating intestinal epithelial barrier function. Mol Biol Cell. American Society for Cell Biology. 2008;19(9):3701–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Berghoff AS, Fuchs E, Ricken G, Mlecnik B, Bindea G, Spanberger T, et al. Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases. Oncoimmunology. 2016;5(1):e1057388.

    Article  PubMed  CAS  Google Scholar 

  11. Berghoff AS, Preusser M. In search of a target: PD-1 and PD-L1 profiling across glioma types. Neuro-Oncology. 2016;18(10):1331–2.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Hubbs JL, Boyd JA, Hollis D, Chino JP, Saynak M, Kelsey CR. Factors associated with the development of brain metastases. Cancer. 2010;116(21):5038–46.

    Article  PubMed  Google Scholar 

  13. Peters S, Bexelius C, Munk V, Leighl N. The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer. Cancer Treat Rev. 2016;45:139–62.

    Article  PubMed  Google Scholar 

  14. D’Antonio C, Passaro A, Gori B, Del Signore E, Migliorino MR, Ricciardi S, et al. Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies. Ther Adv Med Oncol. 2014;6(3):101–14.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  15. Herrlinger U, Förschler H, Küker W, Meyermann R, Bamberg M, Dichgans J, et al. Leptomeningeal metastasis: survival and prognostic factors in 155 patients. J Neurol Sci. 2004;223(2):167–78.

    Article  PubMed  Google Scholar 

  16. Bronte G, Rolfo C, Giovannetti E, Cicero G, Pauwels P, Passiglia F, et al. Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects. Crit Rev Oncol Hematol. 2014;89(2):300–13.

    Article  PubMed  Google Scholar 

  17. Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol. 2005;23(11):2556–68.

    Article  CAS  PubMed  Google Scholar 

  18. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129–39.

    Article  CAS  PubMed  Google Scholar 

  19. Eichler AF, Kahle KT, Wang DL, Joshi VA, Willers H, Engelman JA, et al. EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer. Neuro-Oncology. 2010;12(11):1193–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Cross DAE, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014;4(9):1046–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Weber B, Winterdahl M, Memon A, Sorensen BS, Keiding S, Sorensen L, et al. Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor. J Thorac Oncol. 2011;6(7):1287–9.

    Article  PubMed  Google Scholar 

  22. Elmeliegy MA, Carcaboso AM, Tagen M, Bai F, Stewart CF. Role of ATP-binding cassette and solute carrier transporters in erlotinib CNS penetration and intracellular accumulation. Clin Cancer Res. 2011;17(1):89–99.

    Article  CAS  PubMed  Google Scholar 

  23. Kitazaki T, Oka M, Nakamura Y, Tsurutani J, Doi S, Yasunaga M, et al. Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells. Lung Cancer. 2005;49(3):337–43.

    Article  PubMed  Google Scholar 

  24. Togashi Y, Masago K, Fukudo M, Terada T, Fujita S, Irisa K, et al. Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer. J Thorac Oncol. 2010;5(7):950–5.

    Article  PubMed  Google Scholar 

  25. Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ, et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 2002;62(20):5749–54.

    CAS  PubMed  Google Scholar 

  26. Kim J-E, Lee DH, Choi Y, Yoon DH, Kim S-W, Suh C, et al. Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis. Lung Cancer. 2009;65(3):351–4.

    Article  PubMed  Google Scholar 

  27. Iuchi T, Shingyoji M, Sakaida T, Hatano K, Nagano O, Itakura M, et al. Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma. Lung Cancer. 2013;82(2):282–7.

    Article  CAS  PubMed  Google Scholar 

  28. Dempke WCM, Edvardsen K, Lu S, Reinmuth N, Reck M, Inoue A. Brain metastases in NSCLC - are TKIs changing the treatment strategy? Anticancer Res. 2015;35(11):5797–806.

    CAS  PubMed  Google Scholar 

  29. Welsh JW, Komaki R, Amini A, Munsell MF, Unger W, Allen PK, et al. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non–small-cell lung cancer. J Clin Oncol. 2013;31(7):895–902.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Lee SM, Lewanski CR, Counsell N, Ottensmeier C, Bates A, Patel N, et al. Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases. JNCI J Natl Cancer Inst. 2014;106(7)

    Google Scholar 

  31. Sequist LV, Yang JC-H, Yamamoto N, O’Byrne K, Hirsh V, Mok T, et al. Phase III study of Afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Onco. 2013;31(27):3327–34.

    Article  CAS  Google Scholar 

  32. Wu Y-L, Zhou C, Hu C-P, Feng J, Lu S, Huang Y, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol Elsevier. 2014;15(2):213–22.

    Article  CAS  Google Scholar 

  33. Schuler M, Wu Y-L, Hirsh V, O’Byrne K, Yamamoto N, Mok T, et al. First-line afatinib versus chemotherapy in patients with non–small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases. J Thorac Oncol. 2016;11(3):380–90.

    Article  PubMed  Google Scholar 

  34. Wang S, Cang S, Liu D. Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. J Hematol Oncol. BioMed Central. 2016;9:34.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  35. Jänne PA, Yang JC-H, Kim D-W, Planchard D, Ohe Y, Ramalingam SS, et al. AZD9291 in EGFR inhibitor–resistant non–small-cell lung cancer. N Engl J Med. 2015;372(18):1689–99.

    Article  PubMed  Google Scholar 

  36. Ricciuti B, Baglivo S, Paglialunga L, De Giglio A, Bellezza G, Chiari R, et al. Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy. Ther Adv Med Oncol. 2017;9(6):387–404.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Yang JC-H, Ahn M-J, Kim D-W, Ramalingam SS, Sequist LV, Su W-C, et al. Osimertinib in pretreated T790M-positive advanced non–small-cell lung cancer: AURA study phase II extension component. J Clin Oncol. 2017;35(12):1288–96.

    Article  CAS  PubMed  Google Scholar 

  38. Zeng Q, Wang J, Cheng Z, Chen K, Johnström P, Varnäs K, et al. Discovery and evaluation of clinical candidate AZD3759, a potent, oral active, central nervous system-penetrant, epidermal growth factor receptor tyrosine kinase inhibitor. J Med Chem. 2015;58(20):8200–15.

    Article  CAS  PubMed  Google Scholar 

  39. Zhang I, Zaorsky NG, Palmer JD, Mehra R, Lu B. Targeting brain metastases in ALK-rearranged non-small-cell lung cancer. Lancet Oncol. 2015;16(13):e510–21.

    Article  CAS  PubMed  Google Scholar 

  40. Metro G, Lunardi G, Floridi P, Pascali JP, Marcomigni L, Chiari R, et al. CSF concentration of crizotinib in two ALK-positive non-small-cell lung cancer patients with CNS metastases deriving clinical benefit from treatment. J Thorac Oncol. 2015;10(5):e26–7.

    Article  PubMed  Google Scholar 

  41. Costa DB, Kobayashi S, Pandya SS, Yeo W-L, Shen Z, Tan W, et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol. 2011;29(15):e443–5.

    Article  PubMed  Google Scholar 

  42. Shaw AT, Kim D-W, Mehra R, Tan DSW, Felip E, Chow LQM, et al. Ceritinib in ALK -rearranged non–small-cell lung cancer. N Engl J Med. 2014;370(13):1189–97.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Seto T, Kiura K, Nishio M, Nakagawa K, Maemondo M, Inoue A, et al. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study. Lancet Oncol. 2013;14(7):590–8.

    Article  CAS  PubMed  Google Scholar 

  44. Shaw A, Mehra R, Tan DSW, Felip E, Chow LQM, Ross Camidge D, et al. BM-32 ∗ ceritinib (LDK378) for treatment of patients with ALK-rearranged (ALK+) Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases (BM) in the ascend-1 trial. Neuro-Oncology. 2014;16(suppl 5):v39–v39.

    Article  Google Scholar 

  45. Kim D-W, Tiseo M, Ahn M-J, Reckamp KL, Hansen KH, Kim S-W, et al. Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase–positive non–small-cell lung cancer: a randomized, multicenter phase II trial. J Clin Oncol. 2017;35(22):2490–8.

    Article  CAS  PubMed  Google Scholar 

  46. Besse B, Le Moulec S, Mazieres J, Senellart H, Barlesi F, Chouaid C, et al. Bevacizumab in patients with nonsquamous non-small cell lung cancer and asymptomatic, untreated BRAIN metastases (BRAIN): a nonrandomized, phase II study. Clin Cancer Res. 2015;21(8):1896–903.

    Article  CAS  PubMed  Google Scholar 

  47. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54(1):8–29.

    Article  PubMed  Google Scholar 

  48. Lee JS, Murphy WK, Glisson BS, Dhingra HM, Holoye PY, Hong WK. Primary chemotherapy of brain metastasis in small-cell lung cancer. J Clin Oncol. 1989;7(7):916–22.

    Article  CAS  PubMed  Google Scholar 

  49. Lassen U, Kristjansen PEG, Hansen HH. Brain metastases in small-cell lung cancer. Ann Oncol. 1995;6(9):941–4.

    Article  CAS  PubMed  Google Scholar 

  50. Brufsky AM, Mayer M, Rugo HS, Kaufman PA, Tan-Chiu E, Tripathy D, et al. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res. 2011;17(14):4834–43.

    Article  CAS  PubMed  Google Scholar 

  51. Olson EM, Abdel-Rasoul M, Maly J, Wu CS, Lin NU, Shapiro CL. Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab. Ann Oncol. 2013;24(6):1526–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Pestalozzi BC, Holmes E, de Azambuja E, Metzger-Filho O, Hogge L, Scullion M, et al. CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01). Lancet Oncol. 2013;14(3):244–8.

    Article  CAS  PubMed  Google Scholar 

  53. Aversa C, Rossi V, Geuna E, Martinello R, Milani A, Redana S, et al. Metastatic breast cancer subtypes and central nervous system metastases. Breast. 2014;23(5):623–8.

    Article  CAS  PubMed  Google Scholar 

  54. Sperduto PW, Kased N, Roberge D, Chao ST, Shanley R, Luo X, et al. The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer. J Neuro-Oncol. 2013;112(3):467–72.

    Article  Google Scholar 

  55. Vu T, Claret FX. Trastuzumab: updated mechanisms of action and resistance in breast cancer. Front Oncol. Frontiers. 2012;2:62.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Stemmler HJ, Kahlert S, Siekiera W, Untch M, Heinrich B, Heinemann V. Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast. 2006;15(2):219–25.

    Article  CAS  PubMed  Google Scholar 

  57. Scott BJ, Kesari S. Leptomeningeal metastases in breast cancer. Am J Cancer Res. 2013;3(2):117–26.

    CAS  PubMed  PubMed Central  Google Scholar 

  58. Bartsch R, Rottenfusser A, Wenzel C, Dieckmann K, Pluschnig U, Altorjai G, et al. Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer. J Neuro-Oncol. 2007;85(3):311–7.

    Article  CAS  Google Scholar 

  59. Yap YS, Cornelio GH, Devi BCR, Khorprasert C, Kim SB, Kim TY, et al. Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survival. Br J Cancer. 2012;107(7):1075–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. 1997;16(7):1647–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Worthylake R, Opresko LK, Wiley HS. ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. J Biol Chem. 1999;274(13):8865–74.

    Article  CAS  PubMed  Google Scholar 

  62. Rusnak DW, Affleck K, Cockerill SG, Stubberfield C, Harris R, Page M, et al. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. Cancer Res. 2001;61(19):7196–203.

    CAS  PubMed  Google Scholar 

  63. Rusnak D, Gilmer TM. The discovery of lapatinib (GW572016). Mol Cancer Ther. 2011;10(11):2019.

    Article  CAS  PubMed  Google Scholar 

  64. Taskar KS, Rudraraju V, Mittapalli RK, Samala R, Thorsheim HR, Lockman J, et al. Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer. Pharm Res. 2012;29(3):770–81.

    Article  CAS  PubMed  Google Scholar 

  65. Bachelot T, Romieu G, Campone M, Diéras V, Cropet C, Dalenc F, et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. 2013;14(1):64–71.

    Article  CAS  PubMed  Google Scholar 

  66. Lin NU, Carey LA, Liu MC, Younger J, Come SE, Ewend M, et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2008;26(12):1993–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Lin NU, Diéras V, Paul D, Lossignol D, Christodoulou C, Stemmler H-J, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res. 2009;15(4):1452–9.

    Article  CAS  PubMed  Google Scholar 

  68. Venur V, Leone J. Targeted therapies for brain metastases from breast cancer. Int J Mol Sci. 2016;17(9):1543.

    Article  PubMed Central  CAS  Google Scholar 

  69. Freedman RA, Gelman RS, Wefel JS, Melisko ME, Hess KR, Connolly RM, et al. Translational breast cancer research consortium (TBCRC) 022: a phase II trial of neratinib for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases. J Clin Oncol. 2016;34(9):945–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Bartsch R, Berghoff AS, Vogl U, Rudas M, Bergen E, Dubsky P, et al. Activity of T-DM1 in Her2-positive breast cancer brain metastases. Clin Exp Metastasis. 2015;32(7):729–37.

    Article  CAS  PubMed  Google Scholar 

  71. Davies MA, Liu P, McIntyre S, Kim KB, Papadopoulos N, Hwu W-J, et al. Prognostic factors for survival in melanoma patients with brain metastases. Cancer. 2011;117(8):1687–96.

    Article  PubMed  Google Scholar 

  72. Flaherty KT, McArthur G. BRAF, a target in melanoma. Cancer. 2010;116(21):4902–13.

    Article  CAS  PubMed  Google Scholar 

  73. Davies MA, Saiag P, Robert C, Grob J-J, Flaherty KT, Arance A, et al. Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol. 2017;18(7):863–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012;13(5):459–65.

    Article  CAS  PubMed  Google Scholar 

  75. Kim ES, Bruinooge SS, Roberts S, Ison G, Lin NU, Gore L, et al. Journal of clinical oncology broadening eligibility criteria to make clinical trials more representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement. J Clin Oncol. 2017;35:3737–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Williams NL, Wuthrick EJ, Kim H, Palmer JD, Garg S, Eldredge-Hindy H, et al. Phase 1 study of ipilimumab combined with whole brain radiation therapy or radiosurgery for melanoma patients with brain metastases. Int J Radiat Oncol Biol Phys. 2017;99(1):22–30.

    Article  CAS  PubMed  Google Scholar 

  77. Kiess AP, Wolchok JD, Barker CA, Postow MA, Tabar V, Huse JT, et al. Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. Int J Radiat Oncol Biol Phys. 2015;92(2):368–75.

    Article  PubMed  PubMed Central  Google Scholar 

  78. Skrepnik T, Sundararajan S, Cui H, Stea B. Improved time to disease progression in the brain in patients with melanoma brain metastases treated with concurrent delivery of radiosurgery and ipilimumab. Oncoimmunology. 2017;6(3):e1283461.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  79. Chen L, Douglass J, Kleinberg L, Ye X, Marciscano AE, Forde PM, et al. Concurrent immune checkpoint inhibitors and stereotactic radiosurgery for brain metastases in non-small cell lung cancer, melanoma, and renal cell carcinoma. Int J Radiat Oncol. 2018;100(4):916–25.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cleveland Clinic Akron General, Akron, OH, USA

    Arrvind Raghunath

  2. Cleveland Clinic Lerner School of Medicine, Department of Internal Medicine, Cleveland, OH, USA

    Arrvind Raghunath

  3. Dana-Farber Cancer Institute, Division of Neuro-Oncology, Boston, MA, USA

    Vyshak Alva Venur

  4. Cleveland Clinic, Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland, OH, USA

    Manmeet S. Ahluwalia

Authors
  1. Arrvind Raghunath
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vyshak Alva Venur
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Manmeet S. Ahluwalia
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Manmeet S. Ahluwalia .

Editor information

Editors and Affiliations

  1. Mayo Clinic, Radiation Oncology, Mayo Clinic School of Medicine Radiation Oncology, Jacksonville, FL, USA

    Daniel M. Trifiletti

  2. Department of Radiation Oncology, Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland, OH, USA

    Samuel T. Chao

  3. Sunnybrook Odette Cancer Centre, Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada

    Arjun Sahgal

  4. University of Virginia, Departments of Neurological Surgery and Radiation Oncology, Charlottesville, VA, USA

    Jason P. Sheehan

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Raghunath, A., Venur, V.A., Ahluwalia, M.S. (2019). Targeted Agents and Immunotherapy. In: Trifiletti, D., Chao, S., Sahgal, A., Sheehan, J. (eds) Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy. Springer, Cham. https://doi.org/10.1007/978-3-030-16924-4_32

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-16924-4_32

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-16923-7

  • Online ISBN: 978-3-030-16924-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation